This database contains 457 studies, archived under the term: "drug therapy"
Click here to filter this large number of results.
The impact of supplemental macular carotenoids in Alzheimer’s disease: A randomized clinical trial
Nolan, John M.,
Loskutova, Ekaterina,
Howard, Alan,
Mulcahy, Riona,
Moran, Rachel,
Stack, Jim,
Bolger, Maggie,
Coen, Robert F.,
Dennison, Jessica,
Akuffo, Kwadwo Owusu,
Owens, Niamh,
Power, Rebecca,
Thurnham, David,
Beatty, Stephen
Background: Patients with Alzheimer’s disease (AD) exhibit significantly less macular pigment (MP) and poorer vision when compared to control subjects. Objective: To investigate supplementation with the macular carotenoids on MP, vision, and cognitive function in patients with AD versus controls. Methods: A randomized, double-blind clinical trial with placebo and active arms. 31 AD patients and […]
Long-term metformin usage and cognitive function among older adults with diabetes
Ng, Tze Pin,
Feng, Liang,
Yap, Keng Bee,
Lee, Tih Shih,
Tan, Chay Hoon,
Winblad, Bengt
Evidence strongly supports the important role of insulin resistance in cognitive decline and dementia and suggests that insulin sensitizers may protect against cognitive decline in diabetic and pre-diabetic individuals. Inconclusive results have been reported in clinical trials of rosiglitazone, an insulin sensitizer that also increases cardiovascular mortality risks. No study has yet reported a protective […]
The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer’s disease: a preliminary investigation
Nathan, Pradeep J.,
Boardley, Rebecca,
Scott, Nicola,
Berges, Alienor,
Maruff, Paul,
Sivananthan, Tharani,
Upton, Neil,
Lowy, Martin T.,
Nestor, Peter J.,
Lai, Robert
Background: The histamine H3 receptor plays a critical role in the negative neuromodulation of neurotransmitters involved in cognitive function. H3 receptor antagonists/inverse agonists have been shown to exert pro-cognitive effects in pre-clinical models. GSK239512 is a potent and selective H₃ receptor antagonist developed for the treatment of cognitive dysfunction in neurodegenerative disorders. In this study […]
Donepezil improves gait performance in older adults with mild Alzheimer’s disease: A phase II clinical trial
Montero-Odasso, Manuel,
Muir-Hunter, Susan W.,
Oteng-Amoako, Afua,
Gopaul, Karen,
Islam, Anam,
Borrie, Michael,
Wells, Jennie,
Speechley, Mark
Background: Gait deficits are prevalent in people with dementia and increase their fall risk and future disability. Few treatments exist for gait impairment in Alzheimer’s disease (AD) but preliminary studies have shown that cognitive enhancers may improve gait in this population. Objective: To determine the efficacy of donepezil, a cognitive enhancer that improves cholinergic activity, […]
Memantine versus donepezil in mild to moderate Alzheimer’s disease: a randomized trial with magnetic resonance spectroscopy
Modrego, P. J.,
Fayed, N.,
Errea, J. M.,
Rios, C.,
Pina, M. A.,
Sarasa, M.
Background and Purpose: To compare memantine with the most prescribed cholinesterase inhibitor (donepezil) from a clinical viewpoint when administered in early phases of Alzheimer disease (AD), and to find out whether memantine may produce changes in brain metabolite concentrations in comparison with donepezil.; Methods: In this comparative rater-blinded parallel group randomized trial we recruited a […]
Effect of cholinergic stimulation in early Alzheimer’s disease – functional imaging during a recognition memory task
Miettinen, Pekka S.,
Pihlajamäki, Maija,
Jauhiainen, Anne M.,
Tarkka, Ina M.,
Gröhn, Heidi,
Niskanen, Eini,
Hänninen, Tuomo,
Vanninen, Ritva,
Soininen, Hilkka
Treatment of Alzheimer’s disease (AD) with acetylcholinesterase inhibitors (AChEI) enhances cholinergic activity and alleviates clinical symptoms. In the present functional magnetic resonance imaging (fMRI) study, we investigated the effect of the AChEI rivastigmine on cognitive function and brain activation patterns during a face recognition memory task. Twenty patients with newly-diagnosed mild AD were administered a […]
Dopamine D₂-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer’s disease patients
Martorana, Alessandro,
Di Lorenzo, Francesco,
Esposito, Zaira,
Lo Giudice, Temistocle,
Bernardi, Giorgio,
Caltagirone, Carlo,
Koch, Giacomo
Dopamine is a neurotransmitter involved in several brain functions ranging from emotions control, movement organization to memory formation. It is also involved in the regulation of mechanisms of synaptic plasticity. However, its role in Alzheimer’s disease (AD) pathogenesis is still puzzling. Several recent line of research instead indicates a clear role for dopamine in both […]